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Visceral leishmaniases (VL) or kala-azar is the most dreaded and devastating amongst the various
forms of leishmaniases. The disease, though localized in certain areas only, has gained immense
importance because of high mortality rate, mainly in children. The parasite is responsible for a
spectrum of clinical syndromes, which can, in most extreme cases, go from an asymptomatic infection
to a fatal form of VL. Chemotherapeutic measures, alone are not sufficient to control and contain
the disease. As an alternate strategy, vaccination is also under experimental and clinical trails.
The situation unquestionably demands the use of proper screening system, rationale chemical
synthesis, vaccine development and targeted vaccine delivery. Thus, development of an acceptable
vaccine is not an easy task.
While the factors, which determine clinical outcomes, are in part, a feature of the parasite, it is the
nature of the host and its genetic make up and immune status that play crucial role. The prerequisite
of reliable animal model is that it should have a considerably good correlation with the clinical
situation and is expected to mimic the pathological features and immunological responses observed
in humans when exposed to a variety of Leishmania spp. with different pathogenic characteristics.
Many experimental animal models like rodents, dogs and monkeys have been developed, each with
specific features, but none accurately reproduces what happens in humans. In addition to the
nature of the host, the major difference between natural and experimental infections is the parasite
inoculum; in natural conditions, the infected sand fly vector deposits a few hundred metacyclic
promastigotes into the dermis of the host, whereas experimental infections are induced by the
injection (subcutaneous or intravenous) of millions of promastigotes grown in axenic cultures in
vitro or amastigotes recovered from infected spleens.
In public health terms, VL is the disease of humans and dogs (which may be considered secondary
or ‘accidental’ hosts in the leishmanial life cycle) who often exhibit severe clinical signs and
symptoms when infected, whereas reservoir hosts generally show a few, minor or no signs. This
situation makes the definition of a suitable laboratory model a difficult one since the various
experimental hosts may behave either like a reservoir or an accidental host.
This review discusses the concept of animal models for VL and provides a critical evaluation of the
most common experimental models and their respective advantages and disadvantages. Particular
emphasis is given to the value of using mouse, hamster, dog and primate models, especially in the
context of testing potential antileishmanial vaccines.
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Review Article
The leishmaniases represent endemic infections
that occur, predominantly, in tropical and subtropical
regions. Currently, the leishmaniases are considered
to be endemic in 88 countries and an estimated
12 million people are infected and 350 million
people live at risk of infection (http:// www.who.int/
emc/discase/leish\leis.html).Leishmaniases are
transmitted by different species of sand flies and they
present a wide spectrum of clinical manifestations:
tegumentary leishmaniasis, ranging from localized
cutaneous and mucocutaneous leishmaniases (CL and
MCL), representing the responsive pole, to diffuse
cutaneous leishmaniasis (DCL) which represents the
unresponsive pole and visceral leishmaniasis (VL)
ranging from sub clinical to fatal disease.
Visceral leishmaniasis (VL or Kala-azar) is the
most devastating type among a complex of
leishmaniasis (cutaneous, mucocutaneous, and
visceral) and is caused by the invasion of the
reticuloendothelial system (spleen, liver and bone
marrow) by the hemoflagellate protozoan parasite,
Leishmania donovani. If left untreated the disease is
almost always fatal. Humans are the main reservoir.
The disease is generally restricted to the areas, which
are heavily infested by the sandfly (Phlebotomus
spp.), the vector of this disease. Although visceral
leishmaniasis is widely distributed throughout the
tropics, it is rampant in the Indian subcontinent and
southwest Asia. Annually, about 500,000 cases of
VL occur worldwide, of which 90 per cent occurs in
India, Sudan, Nepal, Bangladesh and Brazil1,2. The
last epidemic of the disease that occurred in India
(Bihar and West Bengal) in 1997-1998 caused an
estimated loss of 20,000 human lives. It should thus
be appreciated that this form of leishmaniasis is of
great public health importance, and if proper
preventive/curative measures are not adapted, the
disease is likely to take a high toll of lives in endemic
areas.
The symptomology of L. donovani infection is
characteristic. The incubation period is usually from
6 wk to 6 months but can be as short as 2 wk or as
long as 9 yr. The initial symptoms consist of malaise,
headache, and fever occurring at irregular intervals
and later becoming of daily occurrence, often
accompanied by chills and sweating. Other symptoms
include cough, diarrhea, dizziness, vomiting,
bleeding of gums, pains in the limbs, and weight loss.
Later, the clinical picture is transformed to
enlargement of spleen and liver, and anemia with
leukopenia and lymphadenopathy. The skin becomes
dark gray, corresponding to the name of the disease
Kala-azar or black sickness.
In most acute infections death may occur within
a few weeks; in sub acute cases within a year and in
chronic cases within 2 to 3 yr. Since, parasites invade
macrophages, which are involved in defense
mechanisms, the Kala-azar patients are invariably
immuno-depressed and promote speedy
multiplication of parasites. The patients thus easily
fall prey to secondary invaders.
Patients, who recovered from VL, usually have
lifelong immunity to reinfection but occasionally
relapses may occur2. The incomplete treatment of
the patient may lead to a condition usually referred
to as post Kala-azar dermal leishmaniasis (PKDL).
This condition has been witnessed very often in
India and occasionally in East Africa. About 20 per
cent of patients in India develop PKDL3. A year or
two after antimony treatment, hypopigmented and
erythematous patches are found on the face, trunk
of the body, and limbs. These may develop into
nodules and resemble those of lepromatous leprosy.
A small number of amastigotes can be seen on the
skin.
Vaccine development
There has been little advancement in the area of
drug development against leishmaniasis and the age
old drugs which have benefited the patient for over
40 yr are still the only hope of patients. Sodium
antimony gluconate (SAG) or Sodium
stibogluconate (SSG) is cardiotoxic at therapeutic
doses recommended for visceral and mucocutaneous
leishmaniases. Further treatment failures reported
with this drug worldwide have often been
interpreted as Sbv or SSG drug resistance2. A second
line drug, amphotericin B, has numerous side
effects,  and pentamidine is associated with
disturbance of glucose metabolism and other
toxicity problems.
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Thus, mere chemotherapy is not sufficient to
combat the disease. Hence, in addition to the
therapeutic measures, vaccination is the point of
serious consideration. Immunization against
leishmaniasis was achieved in the past by inoculating
humans with living parasites that induced localized
self-healing cutaneous lesions (leishmanization).
Since then, a first generation of vaccines composed
of formulations including killed parasites were
developed against cutaneous but not visceral
leishmaniasis and were used in large clinical trials
on human populations of endemic areas4-7. Second
generation vaccines can be divided into three
categories according to their composition: live
mutant vaccines, defined subunits, and crude
fractions. Among the recombinant and native
antigens tested in murine models, the LACK protein8,
the LPGAP peptides9, the LeIF protein10 and the dp72
glycoprotein of L. donovani11 were protective
immunogens for mice. Finally, protection results
obtained with the third generation vaccines composed
of cDNA encoding leishmanial antigens cloned into
a eukaryotic expression vector are still in preliminary
stage4. Although a great number of antigens have
been tested for protection against the cutaneous
disease with in vitro cell or mouse models, no
effective vaccine against human kala-azar is yet
available. Though, the solid immunity observed
following cure of kala-azar has suggested that the
vaccination to prevent leishmaniasis is within the
reach of conventional immunization methods12, only
few reports in literature deal with vaccines viz., FML,
FML-QuilA Saponin etc., against canine visceral
leishmaniasis13-15.
To date, there are no vaccines against visceral
leishmaniasis. However, there is consensus that in the
long term, vaccines ought to become a major tool in
the control of this group of diseases. Unfortunately, the
development of vaccines has been hampered by
significant antigenic diversity and the fact that the
parasites have a digenetic life cycle in at least two hosts
(sand fly vector and human, but there is also an animal
reservoir). An equally important consideration for the
design and implementation of anti parasite vaccines in
general is the contribution of the genetics of the target
host population and their susceptibility to infection and
disease, i.e., the severity of disease manifestations.
Evidence indicates that visceral leishmaniasis did
not get the attention that it deserved because, until
the late 1940s the disease was a local problem and
the world’s attention was engaged in tackling the
highly fatal and epidemic bacterial and viral
infections. The problem was further aggravated by
lack of a proper laboratory animal model to screen
potential antileishmanial compounds or vaccines,
which had serious repercussions on the screening
system; as such the human served both as the
experimental and clinical subjects.
The development of a vaccine against
leishmaniasis is a long term goal in both human and
veterinary medicine. In the past decade, various
subunit and DNA antigens have been identified as
potential vaccine candidates in experimental animals
but none have so far been approved for human use.
Vaccine formulation with killed parasites is still
attractive in terms of cost. To date there is no vaccine
against VL in routine use anywhere in the world.
Several vaccine preparations are in more or less
advanced stages of testing15-21.  The situation
unquestionably demands the use of a proper screening
system. A careful appraisal of these aspects would
certainly lead to success in the development of much
needed antileishmanial agents. We present here a
comprehensive scenario of the laboratory models and
screening systems in use.
Host immune response
Infection begins when an infected female sand fly
takes a blood meal from a human host. Following
inoculation into the skin by the sand fly bite, the
flagellated promastigotes penetrate into the
macrophage, transform into amastigotes and
multiply. The infected macrophage eventually bursts
and the released parasites are able to infect new
phagocytic cells. When the infected host is bitten by
another female sand fly, parasites are ingested and
the life cycle continues. The incubation period of VL
is estimated to range from two to four months. The
disease can present an acute, sub acute or chronic
evolution, but most infected individuals remain
completely asymptomatic. The asymptomatic
individual is characterized by positive serology to
Leishmania and, possibly, a positive intradermal test.
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Infected individuals can evolve to a subclinical form
of VL or directly to an overt form of disease (classical
VL). The classical manifestations of VL are fever,
cough, weight loss, weakness, diarrhoea or dysentery,
and abdominal swelling. Patients also present severe
cachexia, pancytopenia (anaemia, thrombocytopenia,
and leukopenia, with neutropenia, marked
eosinopenia, and a relative lymphocytosis and
monocytosis), oedema, bleeding episodes, huge
hepatosplenomegaly (splenomegaly usually
predominates), and hypergammaglobulinaemia
(mainly IgG from polyclonal B-cell activation) with
hypoalbuminaemia.
VL is a potentially fatal disease and develops
life long immunity against reinfection. Human VL
caused by L. donovani or L. infantum is a severe
disease with generalized spread of the parasites to
reticuloendothelial system, such as spleen, liver and
bone marrow. In communities exposed to infection,
individuals develop a strong cellular immunity in
age related fashion22. There are several studies
indicating that a Th2 type response predominates
during acute disease, such as suppression of T-cell
reactivity to Leishmania antigens, predominance of
endogenous interleukin-4 (IL-4) over interferon-γ
(IFN-γ) production, and polyclonal B-cell activation
resulting in hypergammaglobulinaemia23.  In
contrast with the L. major mouse model, however,
other studies indicate that both Th1 and Th2 like
cells appear to be activated during the course of the
disease, as revealed by the simultaneous high levels
of IFN-γ and IL-10 detected in patients24. Further,
upregulation of IL-10, rather than IL-4, appears to
be a constant feature in clinical disease. This
cytokine has been associated to the immune
suppression commonly seen in VL patients25 and to
the development of PKDL26, a skin manifestation
caused by L. donovani after apparent VL healing27.
Taken together, the above findings provide evidence
for the existence of a Th1/Th2 dichotomy in the
T-cell response also in human leishmaniases.
Interestingly, the outcome of the infection appears
to be determined and regulated by the balance
between the two parasite-specific T-cell
populations27. Thus, even in humans it is difficult
to demarcate the responses leading either to visceral
disease or to protective immunity with L. donovani.
Studies of tissue cytokine mRNA expression
reveal a role for IL-10 in downregulating CD4+T-
cell responses and the involvement of IL-10 in
disease pathology of L. donovani infections28.
However, active VL also finds correlation with
enhanced induction of IFN-γ, lL-2, IL-10 and IL-4.
After cure, levels of IFN-γ, IL-4 and IL-10 persist
suggesting a co-existence of Thl and Th2 in kala-
azar patients as well as in cured individuals28-33.
Individuals with overt visceral leishmaniasis
display a negative skin test response to Leishmania
antigens. Further, peripheral blood mononuclear cells
from such individuals fail to proliferate or to produce
IFN-γ when exposed to specific antigen in vitro34.
Interestingly, failure of peripheral blood
mononuclear cells (PBMC) from recently infected
infants to produce this cytokine is predictive of
evolution of the disease towards classical, patent
visceral leishmaniasis, whereas conversely,
production of IFN-γ  in vitro  is indicative of
maintenance of the infection at a subclinical level.
These observations point to the critical importance
of early T-cell activation patterns in determining the
eventual outcome of the infection.
Which mechanisms underlie the poor T-cell
reactivity to Leishmania antigens characteristic of
patients with active disease? Much of this effect
might be due to unbalanced production of IL-10.
Indeed, elevated blood levels of IL-10 as well as high
production of this cytokine (or its mRNA) by lymph
node cells or PBMC from kala-azar patients appears
to be a hallmark of this form of infection25,35,36,
whereas cell populations collected from cured
individuals fail to express this immunomodulatory
molecule. Of high interest, neutralizing anti-IL-10
monoclonal antibody added to PBMC from acutely
infected patients markedly increased the proliferative
response to a Leishmania lysate25. In this connection,
an antigen of L. infantum (papLe22, a 22-kDa
“potentially aggravating protein” of Leishmania) has
been described, which stimulated IL-10 production
by mononuclear cells from VL patients37. IL-10
therefore, appears to constitute a major regulatory
cytokine whose production may critically control the
outcome of infection. Failure to produce IL-12 has
similarly been associated with the active form of the
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Table I. Experimental models used for vaccine trials against visceral leishmaniasis (VL)
Animal/strains Parasite Route of inoculation Characteristics
Mouse:
BALB/b L. chagasi i.v -Self curing to non healing type
BALB/c L. donovani i.d -Th1/Th2 response
C57BL/6 L. infantum s.c -All immunological reagents are available
-Good model for dissecting protective immune response
Hamster:
Golden L. chagasi s.c -Progressive fatal infection
Chinese L. donovani i.p -Severe immunosuppression (Th2 response)
L. infantum i.c -Reagents for T-cell response not available
-Good experimental model for initial vaccine trial
Dog:
Stray L. infantum i.v -Natural reservoir (not in India)
Beagle L. chagasi i.d -Subclinical/asymptomatic to progressive fatal infection
Mongrel -Immunosuppression (Th2 response)-Reagents for
cytokine response not available-Good secondary model for
pre clinical vaccine trial
Monkey:
Owl L. donovani i.v. -Sub clinical to fulminating progressive fatal infection
Squirrel i.d -Severe immunosuppression (Th2 response)
Vervet -All immunological reagents are available
Langurs -Good secondary model for pre clinical vaccine trial but
difficult to use due to cost,  handling and immunological
black boxes
i.v., intravenous; i.d., intradermal; s.c., subcutaneous; i.p., intraperitonial; i.c., intracardial
disease38. It is also being suggested that unbalanced
IL-10 production might play a role in progression of
the disease towards the cutaneous form of the
infection known as PKDL25.
Selection of models for testing of vaccine
Animal models are expected to mimic the
pathological features and immunological responses
observed in humans when exposed to a variety of
Leishmania  spp. with different pathogenic
characteristics. Many experimental models have been
devel-oped, each with specific features, but none
accurately reproduces what happens in hu-mans. For
in vivo testing of vaccine several animal species have
served as experimental host for VL (Table I).
Important among them are BALB/c mice and Syrian
golden hamster (primary tests), dogs (secondary
tests) and monkeys viz., squirrel, vervet and Indian
langur monkeys as tertiary screens.
In natural conditions, the infected sandfly deposits
a few hundred metacyclic promastigotes into the
dermis of the host, whereas experimental infections
are usually induced by subcutaneous (s.c.) or
intravenous (i.v.) injection of millions of
promastigotes grown under in vitro conditions or
amastigotes recovered from cutaneous lesions or
infected spleens. In each particular laboratory animal,
the outcome of infection (e.g., whether an infection
remains restricted to the site of inoculation or
visceralizes) will depend on a combination of factors,
including the Leishmania species injected, virulence
of the parasite isolate, nature of the inoculum and
the route of inoculation. A suitable laboratory host
for the target parasite (L. donovani) is very important
from the point of view of conducting research on
various aspects including host-parasite interactions,
pathogenesis, biochemical changes, prophylaxis, and
maintenance of parasites and above all evaluation of
antileishmanial action of newer compounds for
development of new drugs. For establishment of
infection in animals there are few criteria viz., (i)
the susceptibility of the animal inoculated, (ii) the
age and particular morphological phase of the
parasite in culture, and (iii) the mode of infection.
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The influence of the inoculum on the outcome is a
particularly important consideration in experimental
models and a wide variety of inoculation routes has
been used. The intradermal (i.d.), subcutaneous (s.c.),
intravenous (i.v.) and intraperitoneal (i.p.) routes are
the most frequently used, but some experimental
studies have reported unexpected results following
the use of more unconventional models of
inoculation. In recent years, there has been a tendency
for inducing an infection similar to natural ways by
using low numbers of infective parasites and the i.d.
route. Of particular interest, in the context, is the
improved infectivity of laboratory isolates when the
inoculum contains sandfly salivary gland extracts of
parasites isolated from sandflies39.
Primary evaluation systems are helpful primarily
in detecting leads for a vaccine development. Since
the host plays an important role in the host-parasite-
vaccine interaction (and we have very little
knowledge about these interactions), every effort
should be made to initiate evaluation of likely
molecules in the target species as early as possible.
This is particularly important if the translation of
activity from test model to target species in the
natural host is contemplated because the behaviour
of the vaccine is likely to be significantly different.
To substantiate the results of primary screening, the
therapeutic trials of vaccines are undertaken under
controlled conditions either against the target parasite
in its natural host or adopted in laboratory animals.
If the efficacy is established and dose relationship
exists, the results of the secondary screening would
help in predicting the dose against the objective
parasite in man. Such an exercise may also serve as
an indication of effective vaccine.
Models for primary testing: Rodents
Several attempts were made in the past to use
small rodents for L. donovani infection. These
includes hamster (European, Chinese and Syrian);
mouse (BALB/c, NMRI, DBA/1, C57BL/6) rat,
mastomys, squirrel, gerbil etc40. Of the various
animals tried, BALB/c mice and Syrian golden
hamsters are the commonest and currently used
animal models for drug and vaccine test ing
against VL.
Mice: Outbreed mice are generally resistant to
infection with L. donovani, but inbred strains display
marked differences in susceptibility, which led, in
the early 1970s, to the isolation of the Lsh
susceptibility gene (subsequently designated
NRAMP1)41. NRAMP1 determines the degree of early
expansion of the parasites in the liver and spleen42.
Studies with the mouse model also led to the
characterization of the immune mechanisms
important for the development of organ specific
immune responses, which cause the clearance of the
parasites from the liver but not the spleen43. Another
important contribution of the mouse model has been
the discovery that chemotherapy is ineffective in the
absence of intact T-cell mediated responses43. These
experimental studies pointed to the need to activate
the immune system for successful chemotherapy and
led to the successful trial in India. The mouse model
has been used widely for the development of vaccines
against VL18,44-46. One of the difficulties with the
mouse as a model for human disease is the need to
inject amastigotes intravenously in order to induce a
reproducible pattern of colonization of the liver and
spleen of wasting, as in the human disease, and the
infection is chronic but not fatal. Recently, an
intradermal murine model of VL has been explored
for the establishment of a chronic infection pattern
in susceptible BALB/c mice resembling a course of
disease similar to that of human VL47. This model
could serve as an important tool in future vaccine
studies against VL.
Different Leishmania species cause clinically
distinct diseases and the severity of the disease
caused by any given parasite can vary markedly
between individual hosts41. Till date, two host
systems have been classified for studying Leishmania
infection on the basis of susceptibility and resistance
of the host. Murine models for experimental
leishmania are well established. Parasites are injected
underneath the skin of the footpad. Most of the mice
strains like C57BL/6, CBA/J, C3H or BIOD2 resist
the infection with clinical cure within few months48;
while BALB/c and all T-cell immunodeficient strains
manifest a systemic visceral leishmania leading to
death49. Resistance and susceptibility are closely
related with the development of T-cell responses of
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Th1 or Th2 type, respectively. C57BL/6 mice mount
early Th1 immune response and prevent the further
growth of the parasite causes self-healing phenotype50
whereas susceptible BALB/c strain mounts early Th2
response and results in non healing lesion and
exaggeration of disease51. Respective resistance and
susceptibility of C57BL/6 and BALB/c strains
depend not only on the Th1 and Th2 type of immune
response of CD4+ T cells but also on the genetic
background of the host.
In general, the immune responses following
infection of inbred mouse strains with viscerotropic
Leishmania  species, such as L. donovani  or
L. infantum, are similar to those observed in the
L. major mouse model. However, BALB/c mice do
not appear to exhibit a similarly high susceptibility
to these parasites, since intravenous injection of
visceral Leishmania results in a self-healing chronic
infection. Further, cytokine phenotypes elicited by
viscerotropic Leishmania in this mouse model are
not typical of a Th2-type response52.
First attempts were the use of killed promastigotes
together with glucan or IL-12 as an adjuvant injected
subcutaneously or intravenously. The effort could
impart partial resistance against challenge infection
in CF1 mice53 Vaccines like live attenuated
promastigotes or genetically manipulated parasites,
were also tested in susceptible (BALB/c) and
resistant (C57BL/6) mice54-56.
This animal has also been used to assess the
efficacy immunization procedures using Leishmania
parasites of low virulence to protect against
infections   by   the viseralizing species57. However,
it is unclear whether these very interesting results
are applicable in other experimental models of
visceral disease. Indeed, in a murine model,
protection   against   visceral   infection allowing
intravenous injection of L. chagasi could be achieved
only by subcutaneous inoculation of high doses of
virulent promastigotes, whereas protection was not
afforded by attenuated or DHFR-TS gene knockouts
from this or other (L. donovani, L. major) species58.
Further, the biopterin transporter (BT1) of
L. donovani  was inactivated by homologous
recombination, the parasite showed a much reduced
capacity to infect BALB/c mice, yet elicited an
immune response characterized by the production of
IFN-γ, leading to a high level of resistance against
challenge by the wild type parasite59.
Immunization with recombinant L. donovani A2
protein, which is regarded as a virulence factor, led
to significant protection against challenge infection
by the homologous parasite, correlating with a mixed
Thl/Th2 as well as a humoral response against the
A2 protein60. BALB/c mice immunized with
recombinant HASPB1 were similarly protected
against L. donovani challenge, as shown by strong
reduction of spleen and liver parasite loads61. Partial
protection was also achieved in BALB/c mice by
subcutaneous injection of the recombinant ORFF and
BTI proteins in complete, followed by incomplete
Freund’s adjuvant62, Recombinant LCR1, a protein
shown to stimulate IFN-γ but not IL-4 production by
T-cell enriched spleen cells from L. chagasi infected
susceptible or resistant mice63.
Though, BALB/c strain of mice infected with
L. (L.) donovani or L. (L.) chagasi is the most widely
studied model of VL, this is considered to be
susceptible wherein the infection progresses during
the first two weeks, and it is then controlled by the
host immune response64. As mentioned above, human
visceral leishmaniasis presents a spectrum of clinical
manifestations from a self-controlled infection to a
progressive disease. The mouse model is comparable
to self-controlled oligosymptomatic cases and
therefore is useful for the study of the protective
immune response. On the other hand, the better model
to study the progressive disease is hamsters infected
with L. (L.) donovani or L. (L.) chagasi that develop
a disease similar to human progressive visceral
leishmaniasis with hepatosplenomegaly,
hypoalbuminaemia, hypergammaglobulinaemia, and
pancytopenia65. Therefore, this model is mainly used
to study the mechanisms of immunosuppression.
Hamster: The Syrian golden hamster (Mesocricetus
auratus) is uniquely susceptible to a variety of
intracellular pathogens and is an excellent model for
a number of human infectious diseases. The golden
hamster was used as one of the early animal models
for the study of visceral leishmaniasis. Infection with
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L. donovani leads to visceral disease and death
making it a useful tool for the characterization of
molecules and mechanisms involved in
pathogenesis40. Hence, they are ideal for most of the
experimental studies including vaccine testing
because they almost mimic the situation in a Kala-
azar patient66. Very few inbred strains of hamsters
are available from commercial sources, limiting the
possibility of genetic manipulations in this model.
In addition to its use as a model of disease, the
hamster is also the favourite laboratory animal for
the isolation and laboratory adaptation of field
isolates40. Hence, these animal models have the
potential to be comparable to the clinical situation.
A major disadvantage of the visceral models is that,
in the prime model of visceral disease (the hamster
model), only high dosages of antimony could
suppress established lesions. The model has also been
used for vaccination studies67,68 but the molecular
basis for this high level of susceptibility is unknown,
and immunological studies related to this model have
been limited by the lack of available reagents.
Interestingly, an inoculum (103 to 105) of L. infantum
promastigotes could result in the development of both
symptomatic and asymptomatic states with a
spontaneous protective response69. Heterologous
protection has been observed using killed L. major
plus BCG combination against L. donovani in
hamsters21.
Melby et al70 described the cloning and sequence
analysis of portions of the Syrian hamster interleukin
2 (IL-2), IL-4, interferon gamma (IFN-γ), tumour
necrosis factor alpha (TNF-α), IL-10, IL-12p40, and
transforming growth factor beta cDNAs. In addition,
they examined the cytokine response to infection with
the intracellular protozoan L. donovani in this animal
model. Sequence analysis of the hamster cytokines
revealed 69 to 93 per cent homology with the
corresponding mouse, rat, and human nucleotide
sequences and 48 to 100 per cent homology with the
deduced amino acid sequences. The hamster IFN-γ,
compared with the mouse and rat homologs, had an
additional 17 amino acids at the C terminus that could
decrease the biological activity of this molecule and
thus contribute to the extreme susceptibility of this
animal to intracellular pathogens. The splenic
expression of these genes in response to infection
with L. donovani, the cause of visceral leishmaniasis
(VL), was determined by Northern blotting. VL in
the hamster is a progressive, lethal disease which very
closely mimics active human disease. In this model
there was pronounced expression of the Th1 cytokine
mRNAs, with transcripts being detected as early as
1 wk post infection. Basal expression of IL-4 in
uninfected hamsters was prominent but did not
increase in response to infection with L. donovani.
IL-12 transcript expression was detected at low levels
in infected animals and paralleled the expression of
IFN-γ. Expression of IL-10, a potent macrophage
deactivator, increased throughout the course of
infection and could contribute to the progressive
nature of this infection. These initial studies are the
first to examine the molecular immunopathogenesis
in a hamster model of VL infection and indicate that
progressive disease in this model of VL is not
associated with early polarization of the splenic
cellular immune response toward a Th2 phenotype
and away from a Th1 phenotype.
Mice control Leishmania infection through the
generation of NO, an effector mechanism that does
not have a clear role in human macrophage
antimicrobial function. Remarkably, since, infection
of the Syrian hamster (M. auratus) with L. donovani
reproduced the clinicopathological features of human
VL, investigation into the mechanisms of disease in
the hamster revealed striking differences from the
murine model. Uncontrolled parasite replication in
the hamster liver, spleen, and bone marrow occurred
despite a strong Th1-like cytokine (IL-2, IFN-γ, and
TNF/lymphotoxin) response in these organs,
suggesting impairment of macrophage effector
function. Indeed, throughout the course of infection,
inducible NO synthase (iNOS, NOS2) mRNA or
enzyme activity in liver or spleen tissue was not
detected. In contrast, NOS2 mRNA and enzyme
activity was readily detected in the spleens of infected
mice. The impaired hamster NOS2 expression could
not be explained by an absence of the NOS2 gene,
overproduction of IL-4, defective TNF/lymphotoxin
production (a potent second signal for NOS2
induction), or early dominant production of the
deactivating cytokines IL-10 and TGF-β. Thus,
although a Th1-like cytokine response was
prominent, the major antileishmanial effector
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mechanism that is responsible for control of infection
in mice was absent throughout the course of
progressive VL in the hamster.
Recent studies have revealed that the mice model
of L. donovani does not reproduce the features of
active human VL like chronic fever,
hepatosplenomegaly, pancytopenia and profound
cachexia and have an ineffective antileishmanial
cellular response66. On the contrary, Syrian golden
hamster model of active VL closely relates the
human counterpart as shown by relentless increase
in visceral parasite burden, progressive
cachexia, hepatosplenomegaly, pancytopenia,
hypergammaglobulinaemia and ultimately death.
While the mice are either intrinsically resistant or
susceptible to Leishmania infection and offer a well
characterized genetic makeup, chiefly by the use of
inbred, recombinant and naturally or experimentally
mutated strains, hamsters provide an excellent model
for an overtly susceptible host. Therefore, hamsters
are used for histopathological and vaccine studies
despite the lack of fine immunochemicals that limit
the mechanistic exploration of immune responses to
Leishmania infection66.
Models for secondary testing: Canines
As all rodent models have the disadvantage of
having different metabolisms and kinetics of the
drugs, eliciting responses different from those seen
in humans, the secondary testing in higher models
such as dogs, cats and monkeys, which have
responses close to human, would further strengthen
the claim of primary screening and would help in
picking the most promising molecules/epitopes,
which need to be pursued in successive steps in a
vaccine development programme. The dog is the
major reservoir of L. infantum in the Middle East
and the Mediterranean region and L. chagasi in South
America. There has been no such reservoir for VL
noticed in India; the disease pattern in dogs and
humans is similar, with a long period of
asymptomatic infection followed by wasting,
anaemia, enlarged lymph nodes, and fever. As in
humans, the infection remains asymptomatic in some
dogs71,72. One of the few differences is the presence
of skin lesions in the dogs, rarely detected in
humans40. The unpredictable nature of the infection
has been a major problem in establishing
experi-mental models for canine VL, but appears to
reflect the spectrum of clinical responses seen in
natural infections.
The dog may be the best animal model for VL in
which relevant immunological studies and vaccine
development could be performed73. With the recent
cloning of several dog genes encoding cytokines and
immunologically important cell markers, as well as
the development of monoclonal antibodies to these
molecules, there is a hope for a more sustained
exploitation of this excellent animal model.  Dog
populations are an important reservoir of
visceralizing leishmania in many endemic areas, and
vaccination of these animals would presumably
constitute a major step towards control of the
infection74. Therefore, dogs have been proposed as a
logical substitute at least for L. infantum, for which
the dog is the natural reservoir. L. donovani also
multiplies within the viscera of mongrel and beagle
dogs. German shepherd dogs have been reported to
give better results than beagles75, whereas some
researchers claimed highly successful infection rates
with mixed breeds71. Studies on the prevalence of
natural infections in dogs indicated that German
shepherds, boxers and Dobermans exhibited VL more
fre-quently than other breeds of dogs71.
In a pilot study by Dunan and colleagues76, 393
seronegative dogs were inoculated with a L. infantum
promastigote fraction (LiF2) previously shown to
induce strong protection against L. major infection
in both susceptible (BALB/c) and resistant (C57BL/
6) mice. The dogs were then released and monitored
for low acquisition of infection by natural routes.
Surprisingly, during the first year after vaccination,
the rate of infection was significantly higher in the
vaccinated group relative to animals injected with
adjuvant alone, a difference that disappeared during
the second year. As similar immunization protocols
had been used in both the mouse and the dog studies,
the authors stressed the differences that may exist
between infection of natural hosts and laboratory
substitutes. In a recent study, dogs from an endemic
area from Brazil were vaccinated subcutaneously (in
the absence of adjuvant) with the fucose-mannose
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ligand (FML) of L. donovani77. This resulted in
strong, long-lasting protection against naturally
acquired infection, with only 8 per cent of the
vaccinated animal developing mild disease (and no
fatal infection), while 33 per cent of the control
population presented with clinical or fatal disease.
Recently FML vaccine and heterologous prime-boost
regime using DNA and vaccinia recombinant vectors
expressing LACK have been tested in canine model
of VL13,15,78.
Models for tertiary or pre clinical testing: Non
human primates
A vaccine for man needs to be tested in primates
due to their close phylogenic relation to humans
in the evolutionary tree. For VL, the availability
of a non human primate model would increase the
understanding of various aspects of host parasite
interactions. Earlier efforts in establishing VL in
New and Old World monkeys demonstrated that
Aotus trivirgatus  (owl monkeys) and Saimiri
sciureus  (Squirrel  monkeys)  developed
fulminat ing but  short  l ived infect ion.
Antileishmanial screening was performed in owl
monkey 79 and squirrel  monkey80.  Old World
monkeys such as Macaca spp. viz., M. mulatta, M.
fascicularis and M. nemestrina, and African vervet
monkeys developed low and/or inconsistent
infections81. Attempts to establish VL in Presbytis
entellus  showed that this species was highly
susceptible to single intravenous inoculation of
hamster spleen- derived L. donovani amastigotes,
which invariably produced consis tent  and
progressive acute fatal infection, leading to death
between 110 to 150 days post infection. The
infected animals  presented al l  the cl inico-
immunopathological features as observed in human
kala-azar82,83. The Indian langurs have also been
used for  precl inical  evaluat ion of  potent ial
antileishmanial drugs68 and vaccine19,20.
Successful vaccination has been achieved against
visceral leishmaniasis by intradermal inoculation of
alum-precipitated autoclaved L. major (ALM) with
BCG and autoclaved L. donovani (ALD) with BCG
in Indian langurs. Vaccinated animals show
significant lymphoproliferative response with high
level of IFN-γ and IL-220,21.
Primates are less fashionable in vaccine
development, because primates are not only
expensive laboratory animals that are difficult to
obtain and to handle, but they are also immunological
black boxes.
Conclusions: Relevance of the experimental
models to clinical infection and immunity
The functions of experimental animal models of
VL are: (i) to provide the means for the in vivo
maintenance of virulent strains of parasites and the
production of amastigotes; ( ii) to study the
pathogenesis of VL and antileishmanial immunity;
(iii) to test antileishmanial drugs and vaccines.
Experimental infections cannot be used to predict
whether an animal can or cannot be incriminated as
a reservoir in the transmission cycle.
The in vivo maintenance of parasites may be done
using a variety of animals; for L. donovani isolates,
the hamster is usually chosen and infection is most
successful when using i.p. or i.c. injection of
amastigotes isolated from the spleen of a previously
infected animal. The modeling of clinical features
of VL is a daunting problem in view of the very
different behaviour of parasites in different hosts and
with different inocula. Paradoxically, any model
where inoculation of parasites is not systematically
followed by disease is deemed inadequate or, at best,
‘capricious’ (as is the case of the canine model),
whereas models where inoculation is rapidly
followed by a fulminating parasite proliferation and
clinical VL (hamster and a majority of primate
models) are considered adequate, despite failing to
follow the pattern observed in humans or dogs40.
The testing of antileishmanial vaccines presents
yet a different set of constraints on models. Various
models may be used to investigate new vaccination
strategies, but in view of the species specificity of
most antigens, it will ultimately be necessary to test
a vaccine in a host permissive for the relevant human
isolates. Thus, the L. major/mouse model is probably
the best choice when investigating the fundamental
immunological factors involved in vaccination
against VL, but not for screening an actual vaccine
against L. donovani84,40. In as much as the function
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Table II.  Evaluation of different vaccines in human and experimental models for visceral leishmaniasis (VL)
Form of vaccine Stage of parasite/Leishmania strain Evaluated in parasite-host system References
Live vaccine Promastigotes/L. tropica L. donovani/Human 85
Promastigotes/L. donovani L. donovani/ Human/Hamster 86, 87, 88
107 amastigotes/L. donovani L. donovani/Hamster 89
107 promastigotes L. chagasi/ Mice 58
Killed vaccine Killed promastigote L. donovani L. donovani/Mice 90
+ glucan
Autoclaved L. donovani +BCG L. donovani/Hamster and Langur 21
108 formaldehyde killed L. donovani/Hamster/Mice 88, 91
promastigotes (UR6)
Autoclaved L. major + BCG L. donovani/Hamster/Langur/Human 19, 20, 7, 92
(Clinical trial) L. infantum/Dog
Killed promastigote of L. infantum L. infantum/ Dog 93
+ FCA
Merthiolated promastigote of L. chagasi/Dog (Phases I-III) 94
L. brazilensis + BCG
BCG alone L. donovani/Hamster 95
Subunit vaccine fraction of  L. donovani+β-1,3-glucan L. donovani/Mice 53
dp72 + C. parvum L. donovani/Mice 44
FML+ FIA/ BCG/ saponin/ IL-12/ L. infantum/Mice/Hamster/ Dog 96, 97, 14, 98, 77
QS 21/ Quil A/ Aluminum hydroxide/
Riedel De Haen
gp36 + Reidel De Haen L. donovani/Mice 99
Eluted gp63 in positive liposome L. donovani/Mice 100
Q protein formulated with BCG L. infantum/Dog 101
LiF2 (L. infantum fraction) L. infantum/Dog (Phases I-III) 76
Glucose regulated protein-78  Mice 102
Integral membrane protein + CFA L. donovani/Hamster 103
Recombinant/ BCG expressing flagellar L. chagasi/Mice 104, 63
Mutant vaccine antigen LCR1/recombinant LCR1
5 x107 promastigote BT1 Null mutant L. donovani/Mice 59
Oligonucleotides primer from L. donovani/Mice 105
L. donovani DNA
ORFF+BT1+ CFA L. donovani/Mice 62
ORFF DNA L. donovani/Mice 106
rHASPB1+ IL12 L. donovani/Mice 61
15 cDNA sub libraries L. donovani/Mice 107
Only papLe 22 cDNA L. donovani/Hamster 108
A2 DNA/ rA2 + heat killed P.acnes L. donovani/Mice 109
IL-12 p40 –p35 fusion cDNA L. donovani/Hamster 66
LACK DNA+ vaccina virus L. infantum/Dog 78
FCA, Freund’s complete adjuvant; FML, fucose-mannose ligand; FIA, Freund’s incomplete adjuvant; CFA, Complete Freund’s
adjuvant
of a vaccine is to transform a susceptible animal into
a resistant one, it may be logical to choose a highly
susceptible animal host for initial vaccine   trials
(e.g., the hamster) and to follow this by trials in a
host which is also a reservoir host (i.e., a host which
could be used in the final stage for exposure to natural
challenge). Many investigators consider the dog as
the best choice for the latter, and have been working
on improving protocols for obtaining more
predictable infection rates. Others have explored the
possibility of using primate hosts, following the
rationale that any vaccine for man needs initial trials
in primates (Table II). However, in view of the fact
that the pattern of leishmanial infection in   primates
is   sub-stantially   different from   that   observed   in
humans, and given the difficulty and costs of
handling primates and the additional problems related
with experimentation on wild-caught animals, there
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does not appear to be a very strong case to support
the use of primates for vaccination trials, particularly
since these animals could never be used for exposure
to natural challenge40.
Further ,  the use of  a  natural  model  of
transmission, using sand fly saliva plus low doses
of parasites has shown that components present in
sand fly saliva can modify the course of infection.
Interest ingly,  new studies in this  area have
emphasized the possibi l i ty  to  use sal iva
components  in  the vaccine design.  Studies
performed in an endemic area for VL have shown
that individuals exposed to uninfected sand flies
can mount an immune response against saliva
components and have shown that some of these
individuals can develop a protective immune
response against Leishmania, upon the encounter
with the parasite110. Therefore, more studies are
required to understand the parasite-vector and host
relationship. By contrast, in vitro studies using
normal human peripheral blood mononuclear cells
(PBMC) stimulated with Leishmania  in vitro
appear to yield results that mimic infection in
humans just as the murine in vitro system mimics
infection in the mouse. Therefore, the human in
vitro system might prove useful for dissecting the
immune response of humans to Leishmania ,
especially during the first few hours and days of
infection, which might prove to be crucial to
understand the immune response of humans to the
parasite. This approach can be used to screen new
parasite antigens as candidates for the development
of a potential vaccine.
References
1. Desjeux P. The increase in risk factors for leishmaniasis
worldwide. Trans R Soc Trop Med Hyg 2001; 95 : 239-43.
2. Sundar S. Drug resistance in Indian visceral leishmaniasis.
Trop Med Int Health 2001; 6 : 849-54.
3. Thakur CP. Epidemiological, clinical and therapeutic
features of Bihar Kala-azar (including PKDL). Trans R Soc
Trop Med Hyg 1984; 78 : 391-8.
4. Handman E. Leishmania vaccines: Old and New. Parasitol
Today 1997; 13 : 236-8.
5. Convit J, Castellano PL, Rondon A, Penardi ME, Ulrich M,
Castes M, et al. Immunotherapy versus chemotherapy in
localized cutaneous leishmaniasis. Lancet 1987; 1 : 401-14.
6. Mayrink W, Magalhães PA, Michalick MSM, Costa CA,
Lima AO, Melo MN, et al. Immunotherapy as treatment of
American cutaneous leishmaniasis: preliminary studies in
Brazil. Parasitologia 1992; 34 : 159-65.
7. Khalil EAG, El Hassan AM, Zijlstra EE, Mukhtar MM,
Ghalib HW, Musa Breyma, et al. Autoclaved Leishmania
major vaccine for prevention of visceral leishmaniasis: a
randomized, double blind, BCG-controlled trial in Sudan.
Lancet 2000; 356 : 1565-9.
8. Gurunathan S, Sacks DL, Brown DR, Reiner SL,
Charest H, Glaichenhaus N, et al. Vaccination with DNA
encoding the immunodominant LACK parasite antigen
confers protective immunity to mice infected with
Leishmania donovani. J Exp Med 1997; 186 : 1137-47.
9. Jardim A, Tolson DL, Turco SJ, Pearson TW, Olafson RW.
The Leishmania donovani lipophosphoglycan T lymphocyte
reactive component is a tightly associated protein complex.
J Immunol 1991; 147 : 3538-44.
10. Skeiky YA, Kennedy M, Kaufman D, Borges MM,
Guderian JA, Scholler JK, et al . LeIF: a recombinant
Leishmania protein that induces IL-12-mediated TH1
cytokine profile. J Immunol 1998; 161 : 6171-9.
11. Jaffe CL, Rachamim N, Sarfstein R. Characterization of two
proteins from Leishmania donovani and their use for
vaccination against visceral leishmaniasis. J Immunol 1990;
144 : 699-706.
12. Muller I, Fruth V, Louis JA. Immunology of experimental
leishmaniasis. Med Microbiol Immunol 1992; 181 : 1-12.
13. Da Silva VO, Borja-Cabrera GP, Correia Pontes NN,
Paraguai de Souza E, Luz KG, Palatnik M, et al. A Phase
III trial of efficacy of the FML-vaccine against canine kala-
azar in an endemic area of Brazil (São Gonçalo do Amarante,
RN). Vaccine 2001; 19 : 1068-81.
14. Borja-Cabrera GP, Mendes AC, Paraguai de Souza E,
Okadab LYH, Trivellato FA, Kawasaki JKA, et al. Effective
immunotherapy against canine visceral leishmaniasis with
the FML-vaccine. Vaccine 2004; 22 : 2234-43.
15. Santos WR, de Lima VMF, Paraguai de Souza E,
Bernardo RR, Palatnik M, Palatnik de Sousa CB. Saponins,
IL12 and BCG adjuvant in the FML-vaccine formulation
against murine visceral  leishmaniasis. Vaccine 2002;
21 : 30-43.
16. Holbrook TW, Cook JA, Parker BW. Immunization against
Leishmania donovani: glucan as an adjuvant with killed
promastigotes. Am J Trop Med Hyg 1981; 30 : 762-8.
17. Jardim A, Alexander J, The HS, Ou D, Olafson RW.
Immunoprotective Leishmania major synthetic T cell
epitopes. J Exp Med 1990; 172 :  645-8.
450 INDIAN J MED RES, MARCH 2006
18. Jaffe CL Greenblatt CL. Reflections of vaccine development
against the intracellular parasite, Leishmania. In: Cryz Jr,
SJ, editor.Vaccine and immunotherapy .  New York:
Pergamon Press; 1991 p. 381-403.
19. Dube A, Sharma P, Srivastava JK, Misra A, Katiyar JC.
Vaccination of langur monkeys (Presbytus entellus) against
Leishmania donovani with autoclaved L. major plus BCG.
Parasitology 1998; 116 : 219-22.
20. Misra A, Dube A, Srivastava B, Sharma P, Srivastava JK,
Katiyar JC, et al. Successful vaccination against Leishmania
donovani infection in Indian langur using alum-precipitated
autoclaved Leishmania major with BCG. Vaccine 2001; 19
: 3485-92.
21. Srivastava JK, Mishra A, Sharma P, Srivastava B, Naik S,
Dube A. Prophylactic potential of autoclaved Leishmania
donovani  with BCG against experimental visceral
leishmaniasis. Parasitology 2003; 127 : 107-14.
22. Bettini S, Gramiccia M, Gradoni L, Pozio E, Mugnai S,
Maroli M. Leishmaniasis in Tuscany (Italy): VIII. Human
population response to leishmanin in the focus of Monte
Argentario (Grosseto) and epidemiological evaluation.
Ann Parasitol Hum Comp 1983; 58 : 539-47.
23. Kharazmi A, Kemp K, Ismail A, Gasim S, Gaafar A,
Kurtzhals JA, et al. T-cell response in human leishmaniasis.
Immunol Lett 1999; 65 : 105-8.
24. Cillari E, Vitale G, Arcoleo F, D’Agostino P, Mocciaro C,
Gambino G, et al. In vivo and in vitro cytokine profiles and
mononuclear cell subsets in Sicilian patients with active
visceral leishmaniasis. Cytokine 1995; 7 : 740-5.
25. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M,
Hashim FA, El-Hassan AM, et al. Interleukin 10 production
correlates with pathology in human Leishmania donovani
infections. J Clin Invest 1993; 92 : 324-9.
26. Gasim SM, Khalil EAG, Ismail A, Kadaro AA, Kharazmi
A, Theander TG. High levels of plasma IL-10 and expression
of IL-10 by keratinocytes during visceral leishmaniasis
predict subsequent development of post-kala-azar dermal
leishmaniasis. Clin Exp Immunol 1998; 111 : 64-9.
27. Kemp M, Theander TG, Kharazmi A. The contrasting roles
of CD4+ T-cells in intracellular infections in human:
Leishmania as an example. Immunol Today 1996; 17 : 13-6.
28. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S.
Splenic cytokine responses in Indian kala-azar before and
after treatment. Clin Infect Dis 1998; 27 : 215-9.
29. Karp CL, EL-Safi SH, Winn TA, Satti MH, Kordojani AM,
Hashim FA, et al. In vivo cytokine profiles in patients with
Kala-azar-Marked elevation of both interleukin 10 and
Interferon-γ. J Clin Invest 1993; 91 : 1644-8.
30. Sunder S, Reed SG, Sharma S, Mehrotra A, Murray HW.
Circulating T helper 1 (Th1) cell and Th2 cell associated
cytokines in Indian patients with visceral leishmaniasis.
Am J Trop Med Hyg 1997; 56 : 522-5.
31. Bahrenscheer J, Kemp M, Kurtzhals JA, Gachihi GS,
Kharazmi A, Theander TG. Interferon-gamma and
interleukin-4 production by human T cells recognizing
Leishmania donovani antigens separated by SDS-PAGE.
APMIS 1995; 103 : 131-9.
32. Cenini P, Berhe N, Hailu A, McGinnes K, Frommel D.
Mononuclear cell subpopulations and cytokine levels in
human visceral leishmaniasis before and after chemotherapy.
J Infect Dis 1993; 168 : 986-93.
33. Kemp M, Kurtzhals JAL, Bendtzen K, Poulsen LK,
Hansen MB, Koech DK, et al. Leishmania donovani specific
Th1 and Th2 like T-cell clones from individuals who have
recovered from visceral leishmaniasis. Infect Immun 1993;
61 : 1069-73.
34. Carvalho EM, Johnson WD, Barreto E, Marsden PD,
Costa JL, Reed S, et al. Cell mediated immunity in American
cutaneous and mucosal leishmaniasis. J Immunol 1985;
135 : 4144-8.
35. Cillari E, Milano S, Dieli M, Arcoleo F, Perego R, Leoni F,
et al. Thymopentin reduces the susceptibility of aged mice
to cutaneous leishmaniasis by modulating CD4 T-cell
subsets. Immunology 1992; 76 : 362-6.
36. Holaday BJ, Pompeu MM, Evans T, DeBraga D,
Texeira MJ, de Queiroz Sousas A, et al. Correlates of
Leishmania-specific immunity in the clinical spectrum of
infection with Leishmania chagasi. J Infect Dis 1993;
167 : 411-7.
37. Suffia I,  Ferrua B, Stien X, Mograbi B, Marty P,
Rousseau D, et al.   A novel Leishmania infantum
recombinant antigen which elicits interleukin 10 production
by peripheral blood mononuclear cells of patients with
visceral leishmaniasis. Infect Immun 2000; 68 : 630-6.
38. Ghalib HW, Whittle JA, Kubin M, Hasim FA,
El-Hassan AM. Interleukin-12 enhances Th1-type responses
in human Leishmania donovani infections. J Immunol 1995;
154 : 4623-9.
39. Handman E. Leishmaniasis: Current status of vaccine
development. Clin Microbiol Rev 2001; 14 : 229-43.
40. Hommel M, Jaffe CL, Travi B, Milon B. Experimental
models for leishmaniasis and for testing anti-leishmanial
vaccines. Ann Trop Med Parasitol 1995; 89 : 55-73.
41. Bradley DJ. Genetic control of natural resistance to
Leishmania donovani. Nature 1974; 250 : 353.
GARG & DUBE:  ANIMAL MODELS FOR KALA-AZAR 451
42. Blackwell JM. Genetic susceptibility to leishmanial
infections: studies in mice and man. Parasitology 1996; 112
: S67-74.
43. Kaye PM, Gorak P, Murphy M, Ross S. Strategies for
immune intervention in visceral leishmaniasis. Ann Trop
Med Parasitol 1995; 89 : 75-81.
44. Rachamim N, Jaffe CL. Pure protein from Leishmania
donovani protects mice gainst both cutaneous and visceral
leishmaniases. J Immunol 1993; 150 : 2322-31.
45. Afrin F, Ali N. Adjuvanticity and protective immunity elicited
by Leishmania donovani antigens encapsulated in positively
charged liposomes. Infect Immun 1997; 65 : 2371-7.
46. Afrin F, Anam K, Ali N. Induction of partial potection
against Leishmania donovani by promastigoyes antigens in
negatively charged liposomes. J Parasitol 2000; 89 : 730-5.
47. Ahmed S, Colmenares M, Soong L, Goldsmith-Pestana K,
Munstermann L, Molina R, et al. Intradermal infection
model for pathogenesis and vaccine studies of murine
visceral leishmaniasis. Infect Immun 2003; 71 : 401-10.
48. Handman E, Ceredig R, Mitchell GF. Murine cutaneous
leishmaniasis: disease patterns in intact and nude mice of
various genotypes and examination of some differences
between normal and infected macrophages. Aust J Exp Biol
Med Sci 1979; 57 : 9-29.
49. Howard JG, Hale CE, Chan-Liew WL. Immunological
regulation of experimental cutaneous leishmaniasis. I.
Immnogenetics aspects of susceptibility to Leishmania
tropica in mice. Parasite Immunol 1980; 2 : 303-14.
50. Lehmann J, Enssle KH, Lehmann I, Emmendorfer A,
Lohmann-Matthes ML. The capacity to produce IFN-gamma
rather than the presence of interleukin-4 determines the
resistance and the degree of susceptibility to Leishmania
donovani infection in mice. J Interferon Cytokine Res 2000;
20 : 63-77.
51. Himmelrich H, Launois P, Maillard I, Biedermann T,
Tacchini- Cottier F, Locksley RM, et al. In BALB/c mice,
IL-4 production during the initial phase of infection with
Leishmania major is necessary and sufficient to instruct Th2
cell development resulting in progressive disease. J Immunol
2000; 164 : 4819-25.
52. Kaye PM, Curry AJ, Blackwell JM. Differential production of
Th1- and Th2-derived cytokines does not determine the
genetically controlled or vaccine-induced rate of cure in murine
visceral leishmaniasis. J Immunol 1991; 146 : 2763-70.
53. Cook JA, Holbrook TW. Immunogenicity of soluble and
particulate antigens from Leishmania donovani: effect of
glucan as an adjuvant. Infect Immun 1983; 40 : 1038-43.
54. Titus RG, Gueiros-Filho F, deFreitas AR, Beverly SM.
Development of a safe live Leishmania vaccine line by gene
replacement. Proc Natl Acad Sci USA 1995; 92 : 10267-71.
55. Veras P, Brodskyn C, Balestieri F, Freitas L, Ramos A,
Queiroz A, et al. A dhfr2ts2 Leishmania major knockout
mutant cross-protects against Leishmania amazonensis.
Mem Inst Oswaldo Cruz 1999; 94 : 491-6.
56. Alexander J, Coombs GH, Mottram JC. Leishmania
mexicana  cysteine proteinase-deficient mutants have
attenuated virulence for mice and potentiate a Th1 response.
J Immunol 1998; 161 : 6794-801.
57. Mukhopadhyay S, Bhattacharyya S, Majhi R, De T, Naskar K,
Majumdar S, et al. Use of an attenuated leishmanial parasite as
an immunoprophylactic and immunotherapeutic agent against
murine visceral leishmaniasis. Clin Diagnos Lab Immunol
2000; 7 : 233-40.
58. Streit, JA, Recker TJ, Filho FG, Beverley SM, Wilson ME.
Protective immunity against the protozoan Leishmania
chagasi is induced by subclinical cutaneous infection with
virulent but not avirulent organisms. J Immunol 2001; 166 :
1921-9.
59. Papadopoulou B, Roy G, Breton M, Kundig C, Dumas C,
Fillion I, et al. Reduced infectivity of a Leishmania donovani
biopterin transporter genetic mutant and its use as an attenuated
strain for vaccination. Infect Immun 2002; 70 : 62-8.
60. Ghosh A, Labrecque S, Maltashewski G. Protection against
Leishmania donovani infection by DNA vaccination:
increased DNA vaccination efficiency through inhibiting the
cellular p53 response. Vaccine 2000; 19 : 3169-78.
61. Stager S, Smith DF, Kaye PM. Immunization with a
recombinant stage-regulated surface protein from
Leishmania donovani induces protection against visceral
leishmaniasis. J Immunol 2000; 165 : 7064-71.
62. Dole VS, Raj VS, Gosh A, Madhubalal R, Myler PJ, Stuart KD.
Immunization with recombinant LD1 antigens protects against
experimental leishmaniasis. Vaccine 2000; 19 : 423-30.
63. Wilson ME, Young BM, Paetz Andersen K, Weinstock JV,
Metwali A, Ali KM, et al. A recombinant Leishmania
chagasi antigen that stimulates cellular immune responses
in infected mice. Infect Immun 1995; 63 : 2062-9.
64. Murray HW, Stern JJ, Welte K, Rubin BY, Carriero SM,
Nathan CF. Experimental visceral leishmaniasis: production
of interleukin 2 and interferon-gamma, tissue immune
reaction, and response to treatment with interleukin-2 and
interferon-gamma. J Immunol 1987; 138 : 2290-7.
65. Rodrigues-Jr V, Silva JS, Campos-Neto A. Selective inability
of spleen antigen presenting cells from Leishmania donovani
infected hamsters to mediate specific T cell proliferation to
parasite antigens. Parasite Immunol 1992; 14 : 49-58.
452 INDIAN J MED RES, MARCH 2006
66. Melby PC, Chandrasekar B, Zhao W, Coe JE. The hamster
as a model of human visceral leishmaniasis: progressive
disease and impaired generation of nitric oxide in the face
of a prominent Th1-like cytokine response. J Immunol 2001;
166 : 1912-20.
67. Sharma P, Rastogi S, Bhatnagar S, Srivastava JK, Dube A,
Guru PY, et al. Antileishmanial action of a plant Tephrosia
pupurea and its fractions against experimental visceral
leishmaniasis. Drug Dev Res 2003; 60 : 285-93.
68. Sharma P, Singh N, Garg R, Haq W, Dube A. Efficacy of
human β-casein fragment (54-59) and its synthetic analogue
compound 89/215 against Leishmania donovani in hamsters.
Peptides 2004; 25 : 1873-81.
69. Requena JM, Alonso C, Soto M. Evolutionarily conserved
proteins as prominent immunogens during Leishmania
infections. Parasitol Today 2000; 16 : 246-50.
70. Melby PC, Tryon VV, Chandrasekar B, Freeman GL. Cloning
of Syrian hamster (Mesocricetus auratus) cytokine cDNAs
and analysis of cytokine mRNA expression in experimental
visceral leishmaniasis. Infect Immun 1998; 66 : 2135-42
71. Abranches P, Santos-Gomes G, Rachamim N, Campino L,
Schnur LF, Jaffe CL. An experimental model for canine
visceral leishmaniasis. Parasite Immunol 1991; 13 : 537-50.
72. Pinelli E, Gonzalo RM, Boog CJP, Rutten VP, Gebhard D,
Ruitenberg EJ, Real de G, et al. Leishmania infantum-specific
T cell lines derived from asymptomatic dogs that lyse infected
macrophages in a major histocopatibility complex-restricted
manner. Eur J Immunol 1995; 25 : 1594-600.
73. Mendonca SCF, de Luca PM, Mayrink W, Restom TF,
Conceicao-Silva AM, Da-Cruz AL, et al. Characterization
of human T lymphocyte-mediated immune responses
induced by a vaccine against American tegumentary
leishmaniasis. Am J Trop Med Hyg 1995; 53 : 195-201.
74. Gradoni L. An update on antileishmanial vaccine candidates
and prospects for a canine Leishmania vaccine. Vet Parasitol
2001; 100 : 87-103.
75. Keenan CM, Hendricks LD, Lightner L, Webster HK,
Johnson AJ. Visceral leishmaniasis in the German shepherd
dog. I. Infection, clinical disease, and clinical pathology.
Vet Pathol 1984; 21 : 74-9.
76. Dunan S, Frommel D, Monjour L, Ogunkolade BW,
Cruz A, Quilici M. Vaccination trial against canine visceral
leishmaniasis. Parasite Immunol 1989; 11 : 397-402.
77. da Silva VO, Borja-Cabrera GP, Correia Pontes NN,
de Souza EP, Luz KG, Palatnik M, et al. A phase III trial of
efficacy of the FML-vaccine against canine kala-azar in an
endemic area of Brazil (Sa˜o Gonc¸alo do Amaranto, RN).
Vaccine 2001; 19 : 1082-92.
78. Ramiro MJ, Zárate JJ,  Hanke T, Rodriguez D,
Rodriguez JR, Esteban M, et al. Protection in dogs against
visceral leishmaniasis caused by Leishmania infantum is
achieved by immunization with a heterologous prime-boost
regime using DNA and vaccinia recombinant vectors
expressing LACK. Vaccine 2003; 21 : 2474-84.
79. Chapman WL, Hanson WL, Hendricks LD. Toxicity and
efficacy of the antileishmanial drug meglumine antimoniate
in the owl monkey (Aotus trivirgatus).  J Parasitol
1983; 69 : 1176-7.
80. Chapman WL, Hanson WL. Visceral leishmaniases in the
squirrel monkey (Saimiri sciureus). J Parasitol 1981;
67 : 740-1.
81. Dube A, Murthy PK, Puri SK, Misra-Bhattacharya S.
Presbytis entellus: a unique primate model for tropical
disease research. Trends Parasitol 2004; 20 : 358-60.
82. Anuradha, Pal R, Guru PY, Katiyar JC. Successful
transmission of Leishmania donovani in langur (Presbytis
entellus). Curr Sci 1990; 59 : 612-5.
83. Dube A, Srivastava JK, Sharma P, Chaturvedi A,
Katiyar JC, Naik S. Leishmania donovani: cellular and
humoral immune responses in Indian langur monkey
Presbytis entellus. Acta Trop 1999; 73 : 37-48.
84. Modabbor, F. Experiences with vaccines against cutaneous
leishmaniasis: of men and mice. Parasitology 1989;
98 : S49.
85. Wyler, DJ, Weinbaum FI, Herrod HR. Characterization of
in vitro proliferative responses of human lymphocytes to
leishmanial antigens. J Infect Dis 1979; 140 : 215-21.
86. Manson-Bahr PEC. Immunity in kala-azar. Trans R Soc Trop
Med Hyg 1961; 55 : 550-5.
87. Manson-Bahr PE, Southgate BA. Recent research on kala
azar in east africa. J Trop Med Hyg 1964; 67 : 79-84.
88. Mukhopadhyay S, Sen P, Bhattacharya S, Mazumdar S,
Roy S. Immunoprophylaxis and immunotherapy against
experimental visceral leishmaniasis. Vaccine 1998; 17 :
289-96.
89. Farrell JP. Leishmania donovani: acquired resistance to visceral
infection in the golden hamster. Exp Parasitol 1976; 40 : 89.
90. Holbrook JW, Cook JA. Immunization of mice against
Leishmania donovani by subcutaneous injection of dead
promastigotes. Am J Trop Med Hyg 1983; 32 : 51-3.
91. Bebars MA, el Serougi AO, Makled KM, Mikhael EM,
Abou Gamra MM, el Sherbiny M, et al. An experimental
vacc ine  p rov id ing  he te ro logous  p ro tec t ion  fo r
Leishmania  species in murine model.  J Egypt  Soc
Parasitol 2000; 30 : 137-56.
GARG & DUBE:  ANIMAL MODELS FOR KALA-AZAR 453
92. Lasri S, Sahibi H, Sadak A, Jaffe CL, Rhalem A. Immune
responses in vaccinated dogs with autoclaved Leishmania
major promastigotes. Vet Res 1999; 30 : 441-9.
93. Panaro MA, Acquafredda A, Lisi S, Lofrumento DD,
Mitolo V, Sisto M, et al . Nitric oxide production by
macrophages of dogs vaccinated with killed Leishmania
infantum  promastigotes.  Comp Immunol Microbiol
Infect Dis 2001; 24 : 187-95.
94. Mayrink W, Genaro O, Dias M, Dacasta CA, Michalick MSM,
Melo MN, et al. Vaccination of dogs against Leishmania
(vianna) braziliansis. Revista do Instituto de Medicina
Tropical de Sao Pauto 1989; 31 : 67.
95. Jarecki-Black JC, Glassman AB, Holbrook TW. The effect
of BCG-vaccine upon experimental visceral leishmaniasis
in hamsters. Ann Clin Lab Sci 1984; 14 : 464-6.
96. Santos WR, Bernardo RR, Pecanha LM, Palatnik M,
Parente JP, Palatnik de Sousa CB. Haemolytic activities
of plant saponins and adjuvants. Effect of Periandra
mediterranea saponin on the humoral response to the FML
antigen of Leishmania donovani. Vaccine  1997; 15 :
1024-9.
97. Santos WR, Paraguai de Souza E, Palatnik M, Palatnik de
Sousa CB. Vaccination of Swiss Albino mice against
experimental visceral leishmaniasis with the FML antigen
of Leishmania donovani. Vaccine 1999; 17 : 2554-61.
98. Santos WR, Aguiar IA, Paraguai de Souza E, de Lima VM,
Palatnik M, Palatnik de Sousa CB. Immunotherapy against
murine experimental visceral leishmaniasis with the FML-
vaccine. Vaccine 2003; 21 : 4668-76.
99. Paraguai de Souza E, Bernardo RR, Palatnik M, Palatnik de
Sousa CB. Vaccination of BALB/c mice against
experimental visceral leishmaniasis with the GP36
glycoprotein antigen of Leishmania donovani. Vaccine 2001;
19 : 3104-15.
100. Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, Ali N.
Characterization of Leishmania donovani  antigens
encapsulated in liposomes that induce protective immunity
in BALB/c mice. Infect Immun 2002; 70 : 6697-706.
101. Molano I, Alonso MG, Miron C, Redondo E, Requena JM,
Soto M, et al. A Leishmania infantum multi-component
antigenic protein mixed with live BCG confers protection
to dogs experimentally infected with L. infantum.
Vet Immunol Immunopathol 2003; 92 : 1-13.
102. Jensen AT, Ismail A, Gaafar A, El Hassan AM, Theander
TG. Humoral and cellular immune responses to glucose
regulated protein 78. a novel Leishmania donovani antigen.
Trop Med Int Health 2002; 7 : 471-6.
103. Garg R, Srivastava JK, Pal A, Dube A. Isolation of integral
membrane proteins of Leishmania promastigotes and
evaluation of their prophylactic potential in hamsters
against experimental visceral leishmaniasis. Vaccine 2005;
23 : 1189-96.
104. Streit JA, Recker TJ, Donelson JE, Wilson ME. BCG
expressing LCR1 of Leishmania chagasi induces protective
immunity in susceptible mice. Exp Parasitol 2000; 94 :
33-41.
105. Campos-Neto A, Soong L, Cordova JL, Sant’Angelo D,
Skeiky YA, Ruddle NH, et al. Cloning and expression of
a Leishmania donovani gene instructed by a peptide
isolated from major histocompatibility complex class II
molecules of infected macrophages. J Exp Med 1995; 182
: 1423-33.
106. Sukumaran B, Tewary P, Saxena S, Madhubala R.
Vaccination with DNA encoding ORFF antigen confers
protective immunity in mice infected with Leishmania
donovani. Vaccine 2003; 21 : 1292-9.
107. Melby PC, Ogden GB, Flores HA, Zhao W, Geldmacher C,
Biediger NM, et al. Identification of vaccine candidates
for experimental visceral leishmaniasis by immunization
with sequential fractions of a cDNA expression library.
Infect Immun 2000; 68 : 5595-602.
108. Fragaki K, Suffia I, Ferrua B, Rousseau D, Le Fichoux Y,
Kubar J. Immunization with DNA encoding Leishmania
infantum protein papLe22 decreases the frequency of
parasitemic episodes in infected hamsters.
Vaccine 2001; 19 : 1701-9.
109. Ghosh A, Zhang WW, Matlashewski G. Immunization with
A2 protein results in a mixed Th1/Th2 and a humoral
response which protects mice against Leishmania donovani
infections. Vaccine 2001; 20 : 59-66.
110. Davies CR, Mazloumi Gavgani AS. Age, acquired immunity
and the risk of visceral leishmaniasis: a prospective study
in Iran. Parasitology 1999; 119 : 247-57.
Reprint requests: Dr (Mrs) Anuradha Dube, Division of Parasitology, Central Drug Research Institute
Post Box No. 173, Lucknow 226001, India
e-mail: anuradha_dube@hotmail.com
454 INDIAN J MED RES, MARCH 2006
